Atmosphere-ph.ru

Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Телефон издательства

Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 2

β-лактамные антибиотики: современная позиция в пульмонологической практике
Н.Б. Лазарева, Е.В. Реброва, М.С. Борисов

Список литературы
1. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. Современные клинические рекомендации по антимикробной терапии. Смоленск: МАКМАХ; 2007. 608 с.
2. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. The European Respiratory Journal 2005 Dec;26(6):1138-80.
3. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, Leinonen M, Saikku P, Myint S. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001 Feb;56(2):109-14.
4. Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, Jorup C, Julander I, Marrie TJ, Mufson MA, Riquelme R, Thalme A, Torres A, Woodhead MA. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. The Journal of Infectious Diseases 2000 Sep;182(3):840-7.
5. Чучалин А.Г., Синопальников А.И., Козлов Р.С., Авдеев С.Н., Тюрин И.Е., Руднов В.А., Рачина С.А., Фесенко О.В. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Consilium Medicum 2015;17(3):8-37.
6. Синопальников А.И., Андреева А.И., Стецюк У. Пневмонии в домах престарелых: современный взгляд на проблему. Клиническая микробиология и антимикробная химиотерапия 2007;9(1):4-19.
7. Crowfoot D, Bunn C, Rogers-Low B, Turner-Jones. A X-ray crystallographic investigation of the structure of penicillin. In: The chemistry of penicillin. Clarke HT, Johnson JR, Robinson R, editors. Princeton, NJ: Princeton University Press; 1949: 310-67.
8. Long AJ, Clifton IJ, Roach PL, Baldwin JE, Rutledge PJ, Schofield CJ. Structural studies on the reaction of isopenicillin N synthase with the truncated substrate analogues delta-(L-alpha-aminoa- dipoyl)-L-cysteinyl-glycine and delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-alanine. Biochemistry 2005 May;449(17):6619-28.
9. Sheehan JC. The chemistry of synthetic and semisynthetic penicillins. Annals of the New York Academy of Sciences 1967 Sep;145(2):216-23.
10. Bousquet PJ, Pipet A, Bousquet-Rouanet L, Demoly P. Oral challenges are needed in the diagnosis of β-lactam hypersensitivity. Clinical and Experimental Allergy 2008 Jan;38(1):185-90.
11. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. Finch R, Greenwood D, Norrby SR, Whitley R, editors. 8th ed. Edinburgh, UK: Churchill Livingstone; 2003. 916 p.; The Journal of Antimicrobial Chemotherapy 2003 Oct;52(4):740-1.
12. Козлов Р.С., Сивая О.В., Пынев К.В. Антибиотикорезистентность в России в 1999–2005 гг., результаты многоцентровых проспективных исследований ПeГАС-I и ПeГАС-II. Клиническая микробиология и антимикробная химиотерапия 2006;8(1):3-47.
13. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В.; группа исследователей проекта ПеГАС. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клиническая микробиология и антимикробная химиотерапия 2010;12(4):329-41.
14. Белькова Ю.А., Рачина С.А., Козлов Р.С. Клинико-экономическая оценка использования цефтаролина фосамила в терапии взрослых госпитализированных пациентов с внебольничной пневмонией пневмококковой этиологии с позиции общества. Клиническая микробиология и антимикробная химиотерапия 2015;17(1):33-52.
15. Neu HC, Wilson AP, Grüneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. Journal of Chemotherapy (Florence, Italy) 1993 Apr;5(2):67-93.
16. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, St Peter SD, Stockwell JA, Swanson JT; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Disease Society of America. Clinical Infectious Diseases 2011 Oct;53(7):617-30.
17. Федеральные рекомендации по лечению внебольничной пневмонии (проект) 2018 г. Доступно по: www.spulmo.ru Ссылка активна на 27.09.2018.
18. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антимикробной химиотерапии. М.: Боргес; 2002. 381 с.
19. Козлов Р.С., Сухорукова М.В., Сидоренко С.В., Эйдельштейн М.В., Склеенова Е.Ю., Иванчик Н.В., Микотина А.В., Гостев В.В., Лазарева И.В., Калиногорская О.С., Волкова М.О., Дехнич А.В. Чувствительность основных возбудителей к цефтаролину в Российской Федерации. Клиническая микробиология и антимикробная химиотерапия 2015;17(3):217-26.
20. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации. Под ред. Яковлева С.В., Рафальского В.В., Сидоренко С.В., Спичак Т.В. М.: Пре100Принт; 2016. 144 с.
21. Newton GG, Abraham EP. Cephalosporin C, a new antibiotic containing sulphur and D-alpha-aminoadipic acid. Nature 1955 Mar;175(4456):548.
22. Velasco J, Luis Adrio J, Angel Moreno M, Díez B, Soler G, Barredo JL. Environmentally safe production of 7-aminodeacetoxycephalosporanic acid (7-ADCA) using recombinant strains of Acremonium chrysogenum. Nature Biotechnology 2000 Aug;18(8):857-61.
23. Baldo BA, Zhao Z, Pham NH. Antibiotic allergy: immunochemical and clinical considerations. Current Allergy and Asthma Reports 2008 Mar(1);8:49-55.
24. Page MG. Emerging cephalosporins. Expert Opinion on Emerging Drugs 2007 Nov;12(4):511-24.
25. Fung-Tomc JC, Huczko E, Stickle T, Minassian B, Kolek B, Denbleyker K, Bonner D, Kessler R. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrobial Agents and Chemotherapy 1995;39:533-8.
26. Bennett PN, Brown MJ. Clinical pharmacology. 9th ed. Toronto, Ontario: Churchill Livingston; 2009. 680 p.
27. Paladino JA, Sunderlin JL, Singer ME, Adelman MH, Schentag JJ. Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance. American Journal of Health-System Pharmacy 2008 Jun; 65(6):1154-9.
28. O’Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation cephalosporin resistance among gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. The Journal of Antimicrobial Chemotherapy 2006 Feb;57(2):356-9.
29. Эйдельштейн М.В., Страчунский Л.С.; исследовательская группа РОСНЕТ. Динамика распространения и чувствительность БЛРС-продуцирующих штаммов энтеробактерий к различным антимикробным препаратам в РИТ. Клиническая микробиология и антимикробная химиотерапия 2005;7(4):26-36.
30. Белобородов В.Б. Клинические перспективы применения цефдиторена пивоксила – нового цефалоспорина 3-й генерации для приема внутрь. Эпидемиология и инфекционные болезни 2016;21(4):219-25.
31. Balbisi EA. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy 2002 Oct;22(10):1278-93.
32. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel antimethicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagnostic Microbiology and Infectious Disease 2008 May;61(1):86-95.
33. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. International Journal of Antimicrobial Agents 2012 Feb;39(2):96-104.
34. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2009 Jun;53(6):2360-6.
35. Singh GS. Beta-lactams in the new millennium. Part-I: monobactams and carbapenems. Mini Reviews in Medicinal Chemistry 2004 Jan;4(1):69-92.
36. Moellering RC Jr. Meeting the challenges of β-lactamases. The Journal of Antimicrobial Chemotherapy 1993 Jan;31(Suppl A):1-8.
37. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000 Aug;406(6797):775-81.
38. Walsh C. Antibiotics, action, origins and resistance. Washington, DC: ASM Press; 2003. 345 p.
39. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Current Opinion in Microbiology 2000 Oct;3(5):489-95.
40. Ambler RP. The structure of β-lactamases. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1980 May;289(1036):321-31.
41. Galleni M, Lamotte-Brasseur J, Raquet X, Dubus A, Monnaie D, Knox JR, Frère JM. The enigmatic catalytic mechanism of active-site serine β-lactamases. Biochemical Pharmacology 1995 May;49(9):1171-8.
42. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 1995 Oct;8(4):557-84.
43. Amyes SGB. Magic bullets, lost horizons: the rise and fall of antibiotics. N.Y.: Taylor and Francis; 2001. 272 p.
44. Samaha-Kfoury JN, Araj GF. Recent developments in b-lactamases and extended-spectrum beta-lactamases. BMJ 2003 Nov;327(7425):1209-13.
45. Colodner R. Extended-spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists. American Journal of Infection Control 2005;33:104-7.
46. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. Worldwide proliferation of carbapenem-resistant gram-negative bacteria. Lancet 1999 Sep;354(9182):955.
47. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin. Laboratory Investigation 2007 Jan;87(1):3-9.
48. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clinical Infectious Diseases 2008 Jun;46(Suppl 5):S350-9.
49. Lewis K. Multidrug resistance pumps in bacteria: variations on a theme. Trends in Biochemical Sciences 1994 Mar;19(3):119-23.
50. Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype of a new family of transporters. Molecular Microbiology 1999 Jan;31(1):394-5.

References
1. Chuchalin AG, Sinopalnikov AI, Strachunskiy LS. Antimicrobial therapy: clinical practice guidelines. Smolensk: IACMAC; 2007. 608 p. (In Russian).
2. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. The European Respiratory Journal 2005 Dec;26(6):1138-80.
3. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, Leinonen M, Saikku P, Myint S. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001 Feb;56(2):109-14.
4. Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, Jorup C, Julander I, Marrie TJ, Mufson MA, Riquelme R, Thalme A, Torres A, Woodhead MA. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. The Journal of Infectious Diseases 2000 Sep;182(3):840-7.
5. Chuchalin AS, Sinopalnikov AI, Kozlov RS, Avdeev SN, Tyurin IE, Rudnov VA, Rachina SA, Fesenko OV. Clinical recommendations for diagnosis, treatment and prevention of severe community-acquired pneumonia in adults. Consilium Medicum 2015;17(3):8-37 (In Russian).
6. Sinopalnikov AI, Andreeva AI, Stetsyuk U. Pneumonia in nursing homes: a modern view on a problem. Clinical Microbiology and Antimicrobial Chemotherapy 2007;9(1):4-19 (In Russian).
7. Crowfoot D, Bunn C, Rogers-Low B, Turner-Jones. A X-ray crystallographic investigation of the structure of penicillin. In: The chemistry of penicillin. Clarke HT, Johnson JR, Robinson R, editors. Princeton, NJ: Princeton University Press; 1949: 310-67.
8. Long AJ, Clifton IJ, Roach PL, Baldwin JE, Rutledge PJ, Schofield CJ. Structural studies on the reaction of isopenicillin N synthase with the truncated substrate analogues delta-(L-alpha-aminoa- dipoyl)-L-cysteinyl-glycine and delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-alanine. Biochemistry 2005 May;449(17):6619-28.
9. Sheehan JC. The chemistry of synthetic and semisynthetic penicillins. Annals of the New York Academy of Sciences 1967 Sep;145(2):216-23.
10. Bousquet PJ, Pipet A, Bousquet-Rouanet L, Demoly P. Oral challenges are needed in the diagnosis of β-lactam hypersensitivity. Clinical and Experimental Allergy 2008 Jan;38(1):185-90.
11. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. Finch R, Greenwood D, Norrby SR, Whitley R, editors. 8th ed. Edinburgh, UK: Churchill Livingstone; 2003. 916 p. The Journal of Antimicrobial Chemotherapy 2003 Oct;52(4):740-1.
12. Kozlov RS, Sivaya OV, Pynev KV. Antibiotic resistance in Russia in 1999–2005: results of multicenter prospective study PeHASus-I and PeHASus-II. Clinical Microbiology and Antimicrobial Chemotherapy 2006;8(1):3-47 (In Russian).
13. Kozlov RS, Sivaya OV, Krechikova OI, Ivanchik NV; PeHASus study group. Antimicrobial resistance of Streptococcus pneumonia in Russia from 1999 to 2009: results of multicenter prospective study PeHASus. Clinical Microbiology and Antimicrobial Chemotherapy 2010;12(4):329-41 (In Russian).
14. Belkova YuA, Rachina SA, Kozlov RS. Clinical and economic assessment of ceftaroline fosamil in treatment of hospitalized adult patients with community-acquired pneumonia of pneumococcal etiology from society viewpoint. Clinical Microbiology and Antimicrobial Chemotherapy 2015;17(1):33-52 (In Russian).
15. Neu HC, Wilson AP, Grüneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. Journal of Chemotherapy (Florence, Italy) 1993 Apr;5(2):67-93.
16. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, St Peter SD, Stockwell JA, Swanson JT; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Disease Society of America. Clinical Infectious Diseases 2011 Oct;53(7):617-30.
17. Community-acquired pneumonia treatment: Federal guidelines (draft) 2018. Available for: www.spulmo.ru Accessed 2018 Sep 27 (In Russian).
18. Strachunskiy LS, Belousov YuB, Kozlov SN. Practical guide to antimicrobial chemotherapy. Moscow: Borges; 2002. 381 p. (In Russian).
19. Kozlov RS, Sukhorukova MV, Sidorenko SV, Edelstein MV, Skleenova EYu, Ivanchik NV, Mikotina AV, Gostev VV, Lazareva IV, Kalinogorskaya OS, Volkova MO, Dekhnich AV. In vitro ceftaroline activity against major bacterial pathogens in Russia: results of multicenter study. Clinical Microbiology and Antimicrobial Chemotherapy 2015;17(3):217-26 (In Russian).
20. Strategy and tactics of antimicrobial agents’ rational use in outpatient practice: Eurasian clinical guidelines. Yakovlev SV, Rafalsky VV, Sidorenko SV, Spichak TV, editors. Moscow: Pre100Print 2016. 144 p. (In Russian).
21. Newton GG, Abraham EP. Cephalosporin C, a new antibiotic containing sulphur and D-alpha-aminoadipic acid. Nature 1955 Mar;175(4456):548.
22. Velasco J, Luis Adrio J, Angel Moreno M, Díez B, Soler G, Barredo JL. Environmentally safe production of 7-aminodeacetoxycephalosporanic acid (7-ADCA) using recombinant strains of Acremonium chrysogenum. Nature Biotechnology 2000 Aug;18(8):857-61.
23. Baldo BA, Zhao Z, Pham NH. Antibiotic allergy: immunochemical and clinical considerations. Current Allergy and Asthma Reports 2008 Mar(1);8:49-55.
24. Page MG. Emerging cephalosporins. Expert Opinion on Emerging Drugs 2007 Nov;12(4):511-24.
25. Fung-Tomc JC, Huczko E, Stickle T, Minassian B, Kolek B, Denbleyker K, Bonner D, Kessler R. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrobial Agents and Chemotherapy 1995;39:533-8.
26. Bennett PN, Brown MJ. Clinical pharmacology. 9th ed. Toronto, Ontario: Churchill Livingston; 2009. 680 p.
27. Paladino JA, Sunderlin JL, Singer ME, Adelman MH, Schentag JJ. Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance. American Journal of Health-System Pharmacy 2008 Jun; 65(6):1154-9.
28. O’Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation cephalosporin resistance among gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. The Journal of Antimicrobial Chemotherapy 2006 Feb;57(2):356-9.
29. Edelstein MV, Strachunskiy LS; ROSNET study group. Trends in prevalence and susceptibility of ESBL-producing Enterobacteriaceae to various antimicrobial agents in Russian ICUs. Clinical Microbiology and Antimicrobial Chemotherapy 2005;7(4):26-36 (In Russian).
30. Beloborodov VB. Clinical prospects for use of cefditoren pivoxyl – a new 3rd generation cephalosporin for oral administration. Epidemiology and Infectious Diseases 2016;21(4):219-25 (In Russian).
31. Balbisi EA. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy 2002 Oct;22(10):1278-93.
32. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel antimethicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagnostic Microbiology and Infectious Disease 2008 May;61(1):86-95.
33. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. International Journal of Antimicrobial Agents 2012 Feb;39(2):96-104.
34. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2009 Jun;53(6):2360-6.
35. Singh GS. Beta-lactams in the new millennium. Part-I: monobactams and carbapenems. Mini Reviews in Medicinal Chemistry 2004 Jan;4(1):69-92.
36. Moellering RC Jr. Meeting the challenges of β-lactamases. The Journal of Antimicrobial Chemotherapy 1993 Jan;31(Suppl A):1-8.
37. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000 Aug;406(6797):775-81.
38. Walsh C. Antibiotics, action, origins and resistance. Washington, DC: ASM Press; 2003. 345 p.
39. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Current Opinion in Microbiology 2000 Oct;3(5):489-95.
40. Ambler RP. The structure of β-lactamases. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1980 May;289(1036):321-31.
41. Galleni M, Lamotte-Brasseur J, Raquet X, Dubus A, Monnaie D, Knox JR, Frère JM. The enigmatic catalytic mechanism of active-site serine β-lactamases. Biochemical Pharmacology 1995 May;49(9):1171-8.
42. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 1995 Oct;8(4):557-84.
43. Amyes SGB. Magic bullets, lost horizons: the rise and fall of antibiotics. N.Y.: Taylor and Francis; 2001. 272 p.
44. Samaha-Kfoury JN, Araj GF. Recent developments in β-lactamases and extended-spectrum β-lactamases. BMJ 2003 Nov;327(7425):1209-13.
45. Colodner R. Extended-spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists. American Journal of Infection Control 2005;33:104-7.
46. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. Worldwide proliferation of carbapenem-resistant gram-negative bacteria. Lancet 1999 Sep;354(9182):955.
47. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin. Laboratory Investigation 2007 Jan;87(1):3-9.
48. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clinical Infectious Diseases 2008 Jun;46(Suppl 5):S350-9.
49. Lewis K. Multidrug resistance pumps in bacteria: variations on a theme. Trends in Biochemical Sciences 1994 Mar;19(3):119-23.
50. Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype of a new family of transporters. Molecular Microbiology 1999 Jan;31(1):394-5.

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]